Indegene

Indegene AAQS

The The AAQS of Indegene (INDGN.NS) as of Oct 22, 2026 is 4. In the previous year, The AAQS was 4.00 — a change of 0.00% (lower).

AAQS

4

YoY

0.00%

Last updated:

Indegene has a current AAQS of 4.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Indegene in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Indegene AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2020
4.00 INR
Jan 1, 2021
4.00 INR
Jan 1, 2022
4.00 INR
Jan 1, 2023
4.00 INR
Jan 1, 2024
4.00 INR
Jan 1, 2025
4.00 INR
Jan 1, 2026
4.00 INR
The Indegene AAQS history
YEARAAQSYoY
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
4—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Indegene Stock analysis

What does Indegene do? Indegene Ltd generates revenue by providing digital-led commercialization services to life sciences companies, including biopharmaceutical, emerging biotech, and medical devices firms. The company assists these clients with drug development, clinical trials, regulatory submissions, pharmacovigilance, complaints management, and the sales and marketing of their products. This comprehensive support structure allows Indegene to serve as a key partner in the end-to-end commercialization process for its diverse client base within the life sciences sector. The company monetizes its offerings through specialized solution segments such as Omnichannel Activation, which helps life sciences companies leverage a digital first approach for optimizing the last-mile promotion of biopharmaceutical products and medical devices to healthcare professionals across multiple channels. Additionally, Enterprise Commercial Solutions primarily involves assisting life sciences companies with their digital marketing operations, further expanding the company's service portfolio and revenue streams. Revenue is also derived from Enterprise Medical Solutions, where Indegene establishes centers of excellence to consolidate large scale regulatory and medical operations for its clients. The company rounds out its business model by offering enterprise clinical solutions and consultancy services, ensuring a holistic service delivery model that addresses various operational needs of its customers in the life sciences industry. Indegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Indegene stock

The AAQS of Indegene is 4 in 2026.

On Eulerpool you can find the complete historical development of The AAQS Indegene since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Indegene

All Key Metrics — Indegene